<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Otorhinolaryngol</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Otorhinolaryngol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-title-group><journal-title>Iranian Journal of Otorhinolaryngology</journal-title></journal-title-group><issn pub-type="ppub">2251-7251</issn><issn pub-type="epub">2251-726X</issn><publisher><publisher-name>Mashhad University of Medical Sciences</publisher-name><publisher-loc>Mashhad, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26788476</article-id><article-id pub-id-type="pmc">4710880</article-id><article-id pub-id-type="publisher-id">ijo-27-279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Neoadjuvant Therapy on Early Complications of Esophageal Cancer Surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rajabi Mashhadi</surname><given-names>Mohammadtaghi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bagheri</surname><given-names>Reza</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Abdollahi</surname><given-names>Abbas</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ghamari</surname><given-names>Mohammad Javad</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shahidsales</surname><given-names>Soudabeh</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shahkaram</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Majidi</surname><given-names>Mohamad Reza</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sheibani</surname><given-names>Shima</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Endoscopic &#x00026; Minimally Invasive Surgery Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><aff id="aff2"><label>2</label><italic>Cardio-Thoracic Surgery &#x00026; Transplant </italic><italic>Research Center, </italic><italic>Emam Reza Hospital</italic><italic>, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><aff id="aff3"><label>3</label><italic>Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><aff id="aff4"><label>4</label><italic>Department of Radiotherapy &#x00026; oncology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><aff id="aff5"><label>5</label><italic>Department</italic><italic> of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><aff id="aff6"><label>6</label><italic>Sinus and Surgical Endoscopic Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</italic></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding Author: Cardio- Thoracic Surgery &#x00026; Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: 0098-0912-346-375, E-mail: ctstrc@mums.ac.ir</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2015</year></pub-date><volume>27</volume><issue>81</issue><fpage>279</fpage><lpage>284</lpage><history><date date-type="received"><day>3</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2013</year></date></history><permissions><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Introduction:</title><p>Early diagnosis and appropriate treatment is required in esophageal cancer due to its invasive nature. The aim of this study was to evaluate early post-esophagectomy complications in patients with esophageal cancer who received neoadjuvant chemoradiotherapy (NACR).</p></sec><sec><title>Materials and Methods:</title><p>This randomized clinical trial was carried out between 2009 and 2011. Patients with lower-third esophageal cancer were randomly assigned to one of two groups. The first group consisted of 50 patients receiving standard chemoradiotherapy (Group A) and then undergoing surgery, and the second group consisted of 50 patients undergoing surgery only (Group B). Patients were evaluated with respect to age, gender, clinical symptoms, type of pathology, time of surgery, perioperative blood loss, and number of lymph nodes resected as well as early post-operative complicate including leakage at the anastomosis site, chylothorax and pulmonary complications, hospitalization period, and mortality rate within the first 30 days after surgery. </p></sec><sec><title>Results:</title><p>The mean age of patients was 55 years. Seventy-two patients had squamous cell carcinoma (SCC) and 28 patients had adenocarcinoma (ACC). There was no significant difference between the two groups with respect to age, gender, time of surgery, complications including anastomotic leakage, chylothorax, pulmonary complications, cardiac complications, deep venous thrombosis (DVT), or mortality. However, there was a significant difference between the two groups regarding hospital stay, time of surgery, perioperative blood loss, and number of lymph nodes resected.</p></sec><sec><title>Conclusion: </title><p>The use of NACR did not increase early post-operative complications or mortality among patients with esophageal cancer. </p></sec></abstract><kwd-group><title>Key Words</title><kwd>Esophageal Cancer</kwd><kwd>Neoadjuvant Therapy</kwd><kwd>Surgery</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Esophageal cancer is the ninth most common cancer in the world and the fifth most common in developing countries (<xref rid="B1" ref-type="bibr">1</xref>). Despite considerable treatment successes, esophageal cancer is still associated with a poor prognosis (<xref rid="B2" ref-type="bibr">2</xref>). Various methods and techniques have been proposed for the treatment of esophageal cancer, yet there is no consensus on the best treatment. The preferred treatment in localized and resectable esophageal cancer is esophagectomy, a procedure which can be performed in different ways (<xref rid="B3" ref-type="bibr">3</xref>). However, local or systemic relapses are common after surgery and the 5-year survival rate varies between 10-39% (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>). The presence of micrometastases in local lymph nodes or distant organs is considered a main prognostic factor for post-operative mortality (<xref rid="B6" ref-type="bibr">6</xref>). </p><p>The key focus in the treatment of this cancer is thus to diagnose such micrometastases prior to surgery and to prevent the formation of macrometas- tases (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Chemoradiotherapy along with surgery leads to good outcomes in the treatment of esophageal cancer, including decreasing the stage of the disease, increasing the chance of cancer eradication, and also elimination of micrometastases (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). </p><p>A number of studies have been reported regarding the benefits of surgery followed by chemoradiotherapy as a neoadjuvant treatment for the management of esophageal cancer (<xref rid="B10" ref-type="bibr">10</xref>-<xref rid="B12" ref-type="bibr">12</xref>). Evidence suggests that this approach may result in increased patient survival rates (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B15" ref-type="bibr">15</xref>). </p><p>However, neoadjuvant treatment has been associated with early post-operative side effects and complications (<xref rid="B16" ref-type="bibr">16</xref>). Such early side effects may be divided into local and systemic complications, including leakage at the anastomosis site, formation of chylothorax, pulmonary complications, wound infection, mediastinal adherence, and also increased difficulty in tumor removal and increased mortality within 30 days after surgery (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>The goal of this study was to evaluate early post-operative side effects of esophagec- tomy among two groups of patients: those undergoing surgery followed by neoadjuvant chemoradiotherapy (NACR) and those undergoing surgery with no NACR.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>This was a randomized clinical trial carried out between 2009 and 2011 in Ghaem and Omid hospitals, Mashhad, both affiliated to Mashhad University of Medical Sciences. One-hundred patients suffering from esophageal cancer were included in the study. Inclusion criteria were (1) lower esophageal cancer; (2) general condition suitable for surgery, as well as lack of previous cardiac, pulmonary, or renal problems; (3) no contraindication to neoadjuvant treatment; and (4) lack of distant macroscopic metastases. </p><p>Exclusion criteria included (1) cervical, upper, and middle-part esophageal cancer; (2) no desire for surgery following NACR; (3) intolerance to surgery after receiving NACR; (4) acute malnutrition (albumin&#x0003c; 2.5g/dl); (5) macrometastases (Stage 4); and (6) serious complication during surgery such as airway damage or intense bleeding.</p><p>Preoperative staging was performed in all patients, including a laboratory examination, endoscopic ultrasound scan&#x000a0;(EUS) and a computed tomography (CT) scan of the thorax and upper abdomen, as well as abdominal sonography and barium swallow. Because of local limitations, it was not possible to perform a positron emission tomography (PET) scan. Patients were randomly assigned to one of two groups using computer-generated random numbers. Group A included 50 patients receiving chemoradiotherapy and cisplatin, followed by 50 Gy radiation and then undergoing surgery 3&#x02013;4 weeks later. The proximal field of radiation therapy was 5&#x02013;7 cm to the tumor and the distal field was adjacent to L<sub>1</sub>. Group B included 50 patients undergoing surgery only.</p><p>The radiation technique consisted of initial anterior and posterior opposed fields at 4,000 cGy. On the first and final days of radiotherapy, patients received chemothera- py with cisplatin (20 mg/m<sup>2)</sup> and 5-fluorouracil (5FU) (700 mg/m<sup>2</sup>/infusion over 24 hours). </p><p>This regimen was administered in all patients who underwent transhiatal esophagectomy, and the stomach was used as a conduit. Anastomosis performed in the neck by hand.</p><p>Epidemiological and clinical information including age, gender, clinical symptoms, type of pathology, time of surgery, perioperative blood loss, number of lymph nodes resected, and early post-operative side effects including leakage at the anastomosis site, pulmonary complications (pneumonia, atelectasis, empyema, and pulmonary insufficiency), chylothorax, resectability of the tumor, hospitalization period, and mortality rate within the first 30 days after surgery were recorded in all patients and then analyzed by SPSS16 on an intention-to-treat basis. </p><p>Categorical variables were compared between the two groups using the chi-square test or Fisher exact test as appropriate, whereas continuous variables were compared using Student&#x02019;s t-test. Differences were considered to be statistically significant for P&#x0003c;0.05.</p></sec><sec sec-type="results"><title>Results</title><p>The age of patients ranged from 48&#x02013;63 years (mean, 55 years). The mean age was 56.0&#x000b1;5.62 years in the group receiving NACR plus surgery and 57.7&#x000b1;3.80 years in the surgery-only group. There was no significant difference between the two groups in terms of age, gender, preoperative staging, or type of pathology. </p><p>There was no significant difference in gender between the two groups (P=0.841) (<xref ref-type="table" rid="T1">Table 1</xref> shows the patient characteristics). The mean hospitalization period was 12.26&#x000b1;1.084 days for Group A and 11.02&#x000b1;1.450 days for Group B. There was a significant difference between the two groups in terms of hospitalization period (P=0.001). </p><p>Anastomosis site leakage was detected in none of the patients in the group receiving NACR plus surgery and one patient in the surgery-only group, although the difference was not statistically significant (P&#x0003e;0.05). </p><p>Pulmonary complications such as atelectasia, pneumonia, empyema, and pulmonary insufficiency were observed in four patients in each of the groups, with no significant difference between the two groups (P&#x0003e;0.99). Chylothorax was observed in two cases in Group A and one case in Group B (P&#x0003e;0.99). In Group A, five patients developed post-operative cardiovascular accidents (myocardial infarction [MI] in three patients and arrhythmia requiring treatment in two patients). </p><p>In Group B, six patients showed complications (three cases of MI and three cases of arrhythmia). </p><p>Two patients from Group A and three patients from Group B developed deep vein thrombosis (DVT) and underwent appropriate treatment. In the first 30 days after surgery, mortalities occurred in four patients in the chemoradiotherapy plus surgery group (two patients due to MI complications and two patients due to pulmonary embolism) and in three patients in the surgery group (two patients due to extensive MI and one patient due to pulmonary embolism). </p><p>There was no significant difference between the two groups (P=1.00). Significant differences between the two groups were identified in terms of time of surgery, perioperative blood loss, and number of lymph nodes resected (<xref ref-type="table" rid="T1">Table.1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#D9D9D9;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Parameter</bold>
</th><th style="background-color:#D9D9D9;" align="center" valign="middle" rowspan="1" colspan="1"/><th style="background-color:#D9D9D9;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Group A</bold>
</th><th style="background-color:#D9D9D9;" align="center" valign="middle" colspan="2" rowspan="1">
<bold>Group B</bold>
</th><th style="background-color:#D9D9D9;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>P-value</bold>
</th></tr></thead><tbody><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Number (Total=100)</td><td align="center" rowspan="4" colspan="1">Stage<break/>I<break/>II<break/>III<break/>IV</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" colspan="2" rowspan="1">50</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Male: female </td><td align="center" rowspan="1" colspan="1">27/23</td><td align="center" colspan="2" rowspan="1">26/24</td><td align="center" rowspan="1" colspan="1">0.841</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Type or pathology (ACC/SCC)</td><td align="center" rowspan="1" colspan="1">15/35</td><td align="center" colspan="2" rowspan="1">13/37</td><td align="center" rowspan="1" colspan="1">0.758</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Preoperative clinical staging</td><td align="center" rowspan="1" colspan="1">Number<break/>0<break/>36<break/>14<break/>0</td><td align="center" rowspan="1" colspan="1">
<break/>
</td><td align="center" rowspan="1" colspan="1">Number<break/>1<break/>34<break/>15<break/>0</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Anastomotic leakage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" colspan="2" rowspan="1">1</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Pulmonary complications</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" colspan="2" rowspan="1">4</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Cardiovascular complications</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5</td><td align="center" colspan="2" rowspan="1">6</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">DVT and related complications</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" colspan="2" rowspan="1">3</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Chylothorax</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" colspan="2" rowspan="1">1</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Duration of hospitalization (days)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12.26<underline>&#x000b1;</underline>1.084</td><td align="center" colspan="2" rowspan="1">11.02<underline>&#x000b1;</underline>1.450</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Hospital mortalities</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" colspan="2" rowspan="1">3</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Blood loss in the surgery</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">405 cc <underline>&#x000b1;</underline> 25</td><td align="center" colspan="2" rowspan="1">390 cc <underline>&#x000b1;</underline> 15</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Time of surgery</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">185 <sub>min</sub>
<underline>&#x000b1;</underline> 20</td><td align="center" colspan="2" rowspan="1">175 min <underline>&#x000b1;</underline> 25</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td style="background-color:#D9D9D9;" align="left" rowspan="1" colspan="1">Number of lymph nodes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 <underline>&#x000b1;</underline> 2</td><td align="center" colspan="2" rowspan="1">7 <underline>&#x000b1;</underline> 2</td><td align="center" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><p>DVT: deep vein thrombosis</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Esophageal cancer is an invasive condition associated with high rates of lymph node involvement and vascular invasion (<xref rid="B6" ref-type="bibr">6</xref>). As an invasive malignant condition, the disease requires very careful management. NACR along with esophagectomy may increase patients&#x02019; survival rate (<xref rid="B4" ref-type="bibr">4</xref>). Furthermore, use of NACR may improve local control of esophageal cancer after surgery (<xref rid="B18" ref-type="bibr">18</xref>). In this study, 100 patients with lower esophageal SCC were included, 50 of whom received NACR and then underwent transhiatal esophagectomy after 3&#x02013;4 weeks and 50 of whom underwent transhiatal esophagectomy without NACR. Factors such as age, gender, tumor location, and clinical stage were evenly balanced between the groups. The mean hospitalization period was 12.26&#x000b1;1.084 days in the group with NACR and 11.02&#x000b1;1.450 days in the other group; a difference that was statistically significant. </p><p>In a study reported by Berger et al (2005) in 179 patients suffering from esophageal cancer, the hospitalization period was the same in both groups (<xref rid="B14" ref-type="bibr">14</xref>). Other studies by Slater et al (2001) and Van Hagen et al (2012) reported similar results (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In a study by Jones (1977) in 166 patients with esophageal cancer, the overall toxicity and side effects of NACR were very small and not clinically relevant (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>In this study there was no significant difference between the two groups with respect to post-operative side effects, such as anastomosis site leakage, pulmonary complications, or wound infection. In a study by Bagheri et al (2011), a group of 40 patients with esophageal cancer receiving NACR were examined and no pulmonary complications were reported (<xref rid="B8" ref-type="bibr">8</xref>). In the study by Van Hagen et al (2012), a group of 366 patients suffering from esophageal cancer were examined and it was noted that only hematological side effects (neutropenia and leucopenia) and general side effects associated with chemoradiotherapy such as lack of appetite and fatigue were higher in the group receiving NACR than the other group, while early post-operative side effects such as anastomosis site leakage, cardiopulmonary complications and wound infection were the same in both groups (<xref rid="B19" ref-type="bibr">19</xref>). Also, in studies by Doty et al (2002) and Slater et al (2011) it was shown that early post-operative side effects in patients receiving NACR did not increase in comparison with the control group (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). In this study, chylothorax was not significantly different in the group receiving NACR compared with the comparator group. In another study by Roul et al (2007) in 818 patients suffering from esophageal cancer, it was reported that early side effects such as anastomosis site leakage, wound infection, and chylothorax did not increase in the patients receiving NACR. On the other hand, cardiac complications such as arrhythmia and MI increased significantly in this group (<xref rid="B17" ref-type="bibr">17</xref>). </p><p>Furthermore, in a study by Berger (2005), there was no significant difference between the two groups in terms of cervical anastomosis site leakage, pneumonia, acute respiratory distress syndrome (ARDS), chylothorax, arrhythmias and wound infection after surgery; only emergence of DVT was higher in the group receiving NACR (<xref rid="B14" ref-type="bibr">14</xref>). In this study, mortalities during the first 30 days after surgery included eight patients from the NACR group and six from the group undergoing surgery only, with no significant difference. Thus NACR does not cause early mortality after esophagectomy. In most studies, such as those reported by Heise (2001) , Berger (2005), and Van Hagen et al (2012), the use of NACR did not cause an increase in mortality rates after surgery (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B22" ref-type="bibr">22</xref>).</p><p>There was no significant difference between the groups receiving or not receiving NACR in terms of early side effects of transhiatal esophagectomy for esophageal SCC. Only the emergence of chylothorax in the group receiving NACR was higher. Therefore, the use of NACR does not cause an increase in early post-operative complications.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The use of NACR did not increase early post-operative complications or mortality among patients with esophageal cancer.</p></sec></body><back><ack><title>Acknowledgements</title><p>This paper has been extracted from the thesis of Dr. Reza Shahkaram entitled &#x0201c;Studying Results of Neoadjuvant Treatment on Early Side Effects of Esophageal Cancer Surgery&#x0201d; which has been done in cardio-thoracic surgery and transplant research center.</p><p> The author hereby wishes to thank the Research Department of Mashhad University of Medical Sciences for their support and approval of proposal number 89376 and Mrs Elham Lotfian for her kind assistance in preparing and revising the paper.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>DA</given-names></name><name><surname>Molloy</surname><given-names>M</given-names></name><name><surname>Pearl</surname><given-names>RH</given-names></name><name><surname>Schutt</surname><given-names>DC</given-names></name><name><surname>Jaques</surname><given-names>DP</given-names></name></person-group><article-title>Appendectomy: a contemporary appraisal</article-title><source> Ann Surg</source><year>1997</year><volume>225</volume><issue>3</issue><fpage>252</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9060580</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Brawley</surname><given-names>O</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths</article-title><source> CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>4</issue><fpage>212</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">21685461</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>B</given-names></name><name><surname>Ilson</surname><given-names>DH</given-names></name><name><surname>Minsky</surname><given-names>BD</given-names></name><name><surname>Bains</surname><given-names>MS</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy</article-title><source> J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">14701767</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Farma</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>WJ</given-names></name><name><surname>Freedman</surname><given-names>G</given-names></name><name><surname>Weiner</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Complete response to neoadjuvant chemora- diotherapy in esophageal carcinoma is associated with significantly improved survival</article-title><source> J Clin Oncol</source><year>2005</year><volume>23</volume><issue>19</issue><fpage>4330</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15781882</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>XF</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>DD</given-names></name></person-group><article-title>Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma</article-title><source> World J Gastroenterol</source><year>2009</year><volume>15</volume><issue>39</issue><fpage>4962</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19842230</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri</surname><given-names>R</given-names></name><name><surname>Maddah</surname><given-names>G</given-names></name><name><surname>Saedi</surname><given-names>HS</given-names></name><name><surname>Sadeghian</surname><given-names>MH</given-names></name><name><surname>Roodbari</surname><given-names>S</given-names></name></person-group><article-title>Bone marrow involvement in esophageal cancer patients who underwent surgical resection</article-title><source> Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>2</issue><fpage>343</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21345693</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonavia</surname><given-names>L</given-names></name><name><surname>Soligo</surname><given-names>D</given-names></name><name><surname>Quiricin</surname><given-names>N</given-names></name><name><surname>Bossolasco</surname><given-names>P</given-names></name><name><surname>Cesana</surname><given-names>B</given-names></name><name><surname>Lembertenghi</surname><given-names>Deliliers G</given-names></name><etal/></person-group><article-title>Bon marrow- disseminated tumor cells in patients with carcinoma of the esophagus or cardia</article-title><source> Surgery</source><year>2001</year><volume>129</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11150029</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri</surname><given-names>R</given-names></name><name><surname>RajabiMashhadi</surname><given-names>MT</given-names></name><name><surname>Ghazvini</surname><given-names>K</given-names></name><name><surname>Asnaashari</surname><given-names>A</given-names></name><name><surname>Zahediyan</surname><given-names>A</given-names></name><name><surname>Sahebi</surname><given-names>MA</given-names></name></person-group><article-title>The effect of neoadjuvant chemoradiotherapy on airway colonization and postoperative respiratory compli- cations in patients undergoing oesopha- gectomy for oesophageal cancer</article-title><source> Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>14</volume><issue>6</issue><fpage>725</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22392934</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelsen</surname><given-names>D</given-names></name></person-group><article-title>Preoperative chemoradiotherapy for esophageal cancer</article-title><source> J Clin Oncol</source><year>2001</year><volume>19</volume><issue>2</issue><fpage>283</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11208816</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urba</surname><given-names>SG</given-names></name><name><surname>Orringer</surname><given-names>MB</given-names></name><name><surname>Turrisi</surname><given-names>A</given-names></name><name><surname>Iannettoni</surname><given-names>M</given-names></name><name><surname>Forastiere</surname><given-names>A</given-names></name><name><surname>Strawderman</surname><given-names>M</given-names></name></person-group><article-title>Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma</article-title><source> J Clin Oncol</source><year>2001</year><volume>19</volume><issue>2</issue><fpage>305</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">11208820</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urschel</surname><given-names>JD</given-names></name><name><surname>Vasan</surname><given-names>H</given-names></name></person-group><article-title>A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer</article-title><source> Am J Surg</source><year>2003</year><volume>185</volume><issue>6</issue><fpage>538</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12781882</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Swisher</surname><given-names>SG</given-names></name><name><surname>Stevens</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients</article-title><source> Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>60</volume><issue>5</issue><fpage>1484</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15590179</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>JI</given-names></name><name><surname>Gooding</surname><given-names>WE</given-names></name><name><surname>Ribeiro</surname><given-names>U Jr</given-names></name><name><surname>Safatle-Ribeiro</surname><given-names>AV</given-names></name><name><surname>Posner</surname><given-names>MC</given-names></name></person-group><article-title>Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma</article-title><source> Arch Surg</source><year>2001</year><volume>136</volume><issue>7</issue><fpage>737</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11448381</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Scott</surname><given-names>WJ</given-names></name><name><surname>Freedman</surname><given-names>G</given-names></name><name><surname>Konski</surname><given-names>A</given-names></name><name><surname>Weiner</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Morbidity and Morality are not increased After induction Chemora- diotheraphy Followed by Esophagectomy in Patients With Esophageal Cancer</article-title><source> Seminars in Oncology</source><year>2005</year><volume>32</volume><issue>9</issue><fpage>16</fpage><lpage>20</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Detterbeck</surname><given-names>FC</given-names></name><name><surname>Egan</surname><given-names>TM</given-names></name><name><surname>Parker</surname><given-names>LA Jr</given-names></name><name><surname>Bernard</surname><given-names>SA</given-names></name><name><surname>Tepper</surname><given-names>JE</given-names></name></person-group><article-title>Induction chemora- diotherapy followed by esophagectomy in patients with carcinoma of the esophagus</article-title><source> Ann Thorac Surg</source><year>1997</year><volume>64</volume><issue>1</issue><fpage>185</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">9236358</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosset</surname><given-names>JF</given-names></name><name><surname>Gignoux</surname><given-names>M</given-names></name><name><surname>Triboulet</surname><given-names>JP</given-names></name><name><surname>Tiret</surname><given-names>E</given-names></name><name><surname>Mantion</surname><given-names>G</given-names></name><name><surname>Elias</surname><given-names>D</given-names></name><etal/></person-group><article-title>Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus</article-title><source> N Engl J Med</source><year>1997</year><volume>337</volume><fpage>161</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9219702</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruol</surname><given-names>A</given-names></name><name><surname>Portale</surname><given-names>G</given-names></name><name><surname>Castoro</surname><given-names>C</given-names></name><name><surname>Merigliano</surname><given-names>S</given-names></name><name><surname>Cagol</surname><given-names>M</given-names></name><name><surname>Cavallin</surname><given-names>F</given-names></name></person-group><article-title>Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer</article-title><source> Ann Surg Oncol</source><year>2007</year><volume>14</volume><issue>11</issue><fpage>3243</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17713823</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>K</given-names></name><name><surname>Takiguchi</surname><given-names>N</given-names></name><name><surname>Wada</surname><given-names>A</given-names></name><name><surname>Takenobu</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Soda</surname><given-names>H</given-names></name><etal/></person-group><article-title>Up-regulated expression of the uridine phosphorylase gene in human gastric tumors is correlated with a favorable prognosis</article-title><source> Anticancer Res</source><year>2006</year><volume>26</volume><issue>6c</issue><fpage>4647</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17214321</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>Hagen P</given-names></name><name><surname>Hulshof</surname><given-names>M</given-names></name><name><surname>Van</surname><given-names>Lanschot J</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Van</surname><given-names>Berge Henegouwen MI</given-names></name><name><surname>Wijnhoven</surname><given-names>B</given-names></name><etal/></person-group><article-title>Preoperative chemoradiotherapy for esophageal or junctional cancer</article-title><source> N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2074</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22646630</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>MS</given-names></name><name><surname>Holland</surname><given-names>J</given-names></name><name><surname>Faigel</surname><given-names>DO</given-names></name><name><surname>Sheppard</surname><given-names>BC</given-names></name><name><surname>Deveney</surname><given-names>CW</given-names></name></person-group><article-title>Does neoadjuvant chemoradiation downstage esophageal carcinoma?</article-title><source> Am J Surg</source><year>2001</year><volume>181</volume><issue>5</issue><fpage>440</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11448438</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doty</surname><given-names>JR</given-names></name><name><surname>Salazar</surname><given-names>JD</given-names></name><name><surname>Forastiere</surname><given-names>AA</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Kleinberg</surname><given-names>L</given-names></name><name><surname>Heitmiller</surname><given-names>RF</given-names></name></person-group><article-title>Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy</article-title><source> Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>1</issue><fpage>227</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12118764</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heise</surname><given-names>JW</given-names></name><name><surname>Heep</surname><given-names>H</given-names></name><name><surname>Frieling</surname><given-names>T</given-names></name><name><surname>Sarbia</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>KA</given-names></name><name><surname>R&#x000f6;her</surname><given-names>HD</given-names></name></person-group><article-title>Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus</article-title><source> BMC Cancer</source><year>2001</year><volume>1</volume><fpage>20</fpage><pub-id pub-id-type="pmid">11737874</pub-id></element-citation></ref></ref-list></back></article>